A family with Camurati-Engelman disease. The role of the missense p.R218C mutation in TGFB1 in bones and endocrine glands

References

1. Cockayne EA. Case for diagnosis. Proc R Soc Med 1920;13:132–6.10.1177/003591572001301935Suche in Google Scholar

2. Camurati M. Di uno raro caso di osteite simmetrica ereditaria degli arti inferiori. Chir Organi Mov 1922;6:662–5.Suche in Google Scholar

3. Engelmann G. Ein Fall von Osteopathia hyperostotica (sclerotisans) multiplex infantilis. Fortschr Geb Roentgenstr Nukl 1929;39:1101–6.Suche in Google Scholar

4. Campos-Xavier B, Saraiva JM, Savarirayan R, Verloes A, Feingold J, et al. Phenotypic variability at the TGF-beta1 locus in Camurati-Engelmann disease. Hum Genet 2001;109:653–8.10.1007/s00439-001-0644-8Suche in Google Scholar PubMed

5. Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 2006;43:1–11.10.1136/jmg.2005.033522Suche in Google Scholar PubMed PubMed Central

6. Sparkes RS, Graham CB. Camurati-Engelmann disease. Genetics and clinical manifestations with a review of the literature. J Med Genet 1972;9:73–85.10.1136/jmg.9.1.73Suche in Google Scholar PubMed PubMed Central

7. Hanson W, Parnes LS. Vestibular nerve compression in Camurati-Engelmann disease. Ann Otol Rhinol Laryngol 1995;104:823–5.10.1177/000348949510401013Suche in Google Scholar PubMed

8. Wright M, Miller NR, McFadzean RM, Riordan-Eva P, Lee AG, et al. Papilloedema, a complication of progressive diaphyseal dysplasia: a series of three case reports. Br J Ophthalmol 1998;82:1042–8.10.1136/bjo.82.9.1042Suche in Google Scholar PubMed PubMed Central

9. Whyte MP, Totty WG, Novack DV, Zhang X, Wenkert D, et al. Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFbeta1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand. J Bone Miner Res 2011;26:920–33.10.1002/jbmr.283Suche in Google Scholar PubMed PubMed Central

10. Crisp AJ, Brenton DP. Engelmann’s disease of bone – a systemic disorder? Ann Rheum Dis 1982;41:183–8.10.1136/ard.41.2.183Suche in Google Scholar PubMed PubMed Central

11. Gupta S, Cheikh IE. Camurati-Engelmann disease in conjunction with hypogonadism. Endocr Pract 2005;11:399–407.10.4158/EP.11.6.399Suche in Google Scholar PubMed

12. Meczekalski B, Czyzyk A, Podfigurna-Stopa A, Rydzewski B, Sroczynski J, et al. Hypothalamic amenorrhea in a Camurati-Engelmann disease – a case report. Gynecol Endocrinol 2013;29:511–4.10.3109/09513590.2012.760196Suche in Google Scholar PubMed

13. Wallace SE, Lachman RS, Mekikian PB, Bui KK, Wilcox WR. Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati-Engelmann disease): report of a four-generation pedigree, identification of a mutation in TGFB1, and review. Am J Med Genet A 2004;129A:235–47.10.1002/ajmg.a.30148Suche in Google Scholar

14. Makita Y, Nishimura G, Ikegawa S, Ishii T, Ito Y, et al. Intrafamilial phenotypic variability in Engelmann disease (ED): are ED and Ribbing disease the same entity? Am J Med Genet 2000;91:153–6.10.1002/(SICI)1096-8628(20000313)91:2<153::AID-AJMG15>3.0.CO;2-USuche in Google Scholar

15. Janssens K, Gershoni-Baruch R, Van Hul E, Brik R, Guanabens N, et al. Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13. J Med Genet 2000;37:245–9.10.1136/jmg.37.4.245Suche in Google Scholar

16. Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 2000;26:19–20.10.1038/79128Suche in Google Scholar

17. Vaughn SP, Broussard S, Hall CR, Scott A, Blanton SH, et al. Confirmation of the mapping of the Camurati-Englemann locus to 19q13. 2 and refinement to a 3.2-cM region. Genomics 2000;66:119–21.10.1006/geno.2000.6192Suche in Google Scholar

18. Oida T, Weiner HL. Depletion of TGF-beta from fetal bovine serum. J Immunol Methods 2010;362:195–8.10.1016/j.jim.2010.09.008Suche in Google Scholar

19. Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-beta1 to the bone. Endocr Rev 2005;26:743–74.10.1210/er.2004-0001Suche in Google Scholar

20. Oklu R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J 2000;352(Pt 3):601–10.10.1042/bj3520601Suche in Google Scholar

21. Shi M, Zhu J, Wang R, Chen X, Mi L, et al. Latent TGF-beta structure and activation. Nature 2011;474:343–9.10.1038/nature10152Suche in Google Scholar

22. Sanchez-Capelo A. Dual role for TGF-beta1 in apoptosis. Cytokine Growth Factor Rev 2005;16:15–34.10.1016/j.cytogfr.2004.11.002Suche in Google Scholar

23. Bensamoun SF, Hawse JR, Subramaniam M, Ilharreborde B, Bassillais A, et al. TGFbeta inducible early gene-1 knockout mice display defects in bone strength and microarchitecture. Bone 2006;39:1244–51.10.1016/j.bone.2006.05.021Suche in Google Scholar PubMed

24. Fox SW, Lovibond AC. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol 2005;243:19–26.10.1016/j.mce.2005.09.008Suche in Google Scholar PubMed

25. Cicek M, Vrabel A, Sturchio C, Pederson L, Hawse JR, et al. TGF-beta inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One 2011;6:e17522.10.1371/journal.pone.0017522Suche in Google Scholar PubMed PubMed Central

26. Dabovic B, Chen Y, Colarossi C, Zambuto L, Obata H, et al. Bone defects in latent TGF-beta binding protein (Ltbp)-3 null mice; a role for Ltbp in TGF-beta presentation. J Endocrinol 2002;175:129–41.10.1677/joe.0.1750129Suche in Google Scholar PubMed

27. Janssens K, ten Dijke P, Ralston SH, Bergmann C, Van Hul W. Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J Biol Chem 2003;278:7718–24.10.1074/jbc.M208857200Suche in Google Scholar PubMed

28. McLennan IS, Koishi K. The transforming growth factor-betas: multifaceted regulators of the development and maintenance of skeletal muscles, motoneurons and Schwann cells. Int J Dev Biol 2002;46:559–67.Suche in Google Scholar

29. Zamani N, Brown CW. Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure. Endocr Rev 2011;32:387–403.10.1210/er.2010-0018Suche in Google Scholar PubMed PubMed Central

30. Ingman WV, Robertson SA. Transforming growth factor-beta1 null mutation causes infertility in male mice associated with testosterone deficiency and sexual dysfunction. Endocrinology 2007;148:4032–43.10.1210/en.2006-1759Suche in Google Scholar PubMed

31. Memon MA, Anway MD, Covert TR, Uzumcu M, Skinner MK. Transforming growth factor beta (TGFbeta1, TGFbeta2 and TGFbeta3) null-mutant phenotypes in embryonic gonadal development. Mol Cell Endocrinol 2008;294:70–80.10.1016/j.mce.2008.08.017Suche in Google Scholar PubMed PubMed Central

32. Coya R, Alvarez CV, Perez F, Gianzo C, Dieguez C. Effects of TGF-beta1 on prolactin synthesis and secretion: an in-vitro study. J Neuroendocrinol 1999;11:351–60.10.1046/j.1365-2826.1999.00336.xSuche in Google Scholar PubMed

33. Sarkar DK, Chaturvedi K, Oomizu S, Boyadjieva NI, Chen CP. Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes. Endocrinology 2005;146:4179–88.10.1210/en.2005-0430Suche in Google Scholar PubMed PubMed Central

34. Zatelli MC, Rossi R, degli Uberti EC. Androgen influences transforming growth factor-beta1 gene expression in human adrenocortical cells. J Clin Endocrinol Metab 2000;85:847–52.Suche in Google Scholar

35. Pisarev MA, Thomasz L, Juvenal GJ. Role of transforming growth factor beta in the regulation of thyroid function and growth. Thyroid 2009;19:881–92.10.1089/thy.2007.0303Suche in Google Scholar

36. Moritani M, Yamasaki S, Kagami M, Suzuki T, Yamaoka T, et al. Hypoplasia of endocrine and exocrine pancreas in homozygous transgenic TGF-beta1. Mol Cell Endocrinol 2005;229:175–84.10.1016/j.mce.2004.08.007Suche in Google Scholar

37. Sobrinho LG. Prolactin, psychological stress and environment in humans: adaptation and maladaptation. Pituitary 2003;6:35–9.10.1023/A:1026229810876Suche in Google Scholar

38. Li XF, Knox AM, O’Byrne KT. Corticotrophin-releasing factor and stress-induced inhibition of the gonadotrophin-releasing hormone pulse generator in the female. Brain Res 2010;1364:153–63.10.1016/j.brainres.2010.08.036Suche in Google Scholar

39. Beighton P. Sclerosing bone dysplasias. Prog Clin Biol Res 1982;104:173–94.Suche in Google Scholar

40. Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 1998;13:1569–76.10.1359/jbmr.1998.13.10.1569Suche in Google Scholar

41. Ziv E, Kahn A, Cauley J, Morin P, Saiz R, et al. No association between the TGF-beta 1 Leu10Pro polymorphism and osteoporosis among white women in the United States. Am J Med 2003;114:227–31.10.1016/S0002-9343(02)01393-1Suche in Google Scholar

42. Inaoka T, Shuke N, Sato J, Ishikawa Y, Takahashi K, et al. Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). Clin Nucl Med 2001;26:680–2.10.1097/00003072-200108000-00003Suche in Google Scholar PubMed

43. Cherie-Ligniere G, Santalena G, Parafioriti A. Pamidronate in the treatment of progressive diaphyseal dysplasia (Camurati-Engelmann disease). Clin Exp Rheumatol 1999;17:264.Suche in Google Scholar

44. Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 2005;3:98–102.10.1007/s11914-005-0017-7Suche in Google Scholar PubMed